130 results on '"Carignan, Damien"'
Search Results
2. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study
3. Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost
4. Differential outcomes of re-stratified high-risk prostate cancer patients treated with external beam radiation therapy plus high-dose-rate brachytherapy boost
5. The association of intraprostatic calcifications and dosimetry parameters with biochemical control after permanent prostate implant
6. 172 The Impact of Androgen-Deprivation Therapy on Ceramides, a Potential Biomarker of Outcomes of Prostate Cancer for Patients Treated with EBRT and HDR Brachytherapy Boost
7. 33 Efficacy of Ultra Hypofrationed Radiotherapy Combined with HDR Brachytherapy
8. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses
9. Activation of innate immunity in primary human cells using a plant virus derived nanoparticle TLR7/8 agonist
10. 1367: Predictors of the risk of metastasis and death in prostate cancer treated with HDR boost.
11. 1335: Ceramides as a potential plasmatic biomarker of outcomes for localized prostate cancer.
12. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine
13. PSOR3 Presentation Time: 11:40 AM
14. PSOR7 Presentation Time: 12:00 PM
15. PP12 Presentation Time: 11:20 AM
16. 154: The Role of CAPRA Score as a Predictor of Outcomes in High-Risk Prostate Cancer Patients Treated with EBRT Plus HDR Brachytherapy Boost
17. 51: Patient’s Reported Outcomes (PROS) of an Ultra-Hypo Fractionated (UHF) Prostate Image Guided Radiation Therapy (IGRT) with Hdr Brachytherapy Boost (BB) as Compared to a Moderate Hypo Fractionated (MHF) Approach: Interim Analysis of a Phase Two Study
18. 50: A Pilot Study of Salvage Hdr Brachytherapy in Recurrent Prostate Cancer: 5 Year Toxicity and Outcomes
19. The Size of the Unbranched Aliphatic Chain Determines the Immunomodulatory Potency of Short and Long Chain n-Alkanols
20. Short-term immunological effects of non-ethanolic short-chain alcohols
21. Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning
22. 34: Infectious Risk After Prostatic Transrectal Fiducial Marker Implantation in Radiation Therapy
23. 6: Ultra-Hypofractionated (UHF) Compared to Moderate-Hypofractionated (MHF) Prostate IGRT with HDR Brachytherapy Boost(BB): Four-Year Toxicities and Local Control
24. 72: Apoptosis and Senescence in Localized Prostate Cancer Tissues Treated with HDR-BT Boost with Radiotherapy (EBRT) and ADT
25. PSOR09 Presentation Time: 12:40 PM: Ceramides as a Potential Biomarker of Treatment Outcome and Toxicities of Prostate Cancer Patients Treated with EBRT and HDR Brachytherapy Boost
26. PP03 Presentation Time: 11:18 AM: Biochemical Prostate Cancer Cure after Ultra Hypofrationned Radiotherapy Combined with HDR Brachytherapy
27. The Dysregulation of the Monocyte/Macrophage Effector Function Induced by Isopropanol Is Mediated by the Defective Activation of Distinct Members of the AP-1 Family of Transcription Factors
28. 15: Acura Analysis of PSA Kinetics and Late Treatment Related Toxicity in a Phase 2 Randomized Pilot Study Comparing High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
29. 14: Seventeen Years Experience of Ebrt Plus Hdr Brachytherapy Boost in High-Risk Localized Prostate Cancer Patients: A Competing Risks Analysis
30. DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy
31. Methanol Induces a Discrete Transcriptional Dysregulation that Leads to Cytokine Overproduction in Activated Lymphocytes
32. 188 DNA Repair Genes Polymorphisms, Tumour Control and Treatment Toxicity in Prostate Cancer Patients Treated with Permanent Implant Prostate Brachytherapy
33. 10 The Impact of Dose to Bladder Neck on Urinary Toxicity in Patients Treated with HDR Brachytherapy Boost for Prostate Cancer
34. 90 Ultra-Hypo (UHF) Compared to Moderate-Hypo (MHF) Fractionated Prostate IGRT with HDR Brachytherapy Boost: Long Term Toxicity, Acceptability and Efficiency of Delivery
35. 173 Image-Guided Brachytherapy for Primary Vaginal Cancer: Clinical and Toxicity Outcomes
36. Feasibility of Intraprostatic Prostate Cancer Imaging with FCH-PET/CT for Preoperative Planning of Image-Guided HDR Brachytherapy
37. The Impact of Dose to Bladder Neck on Urinary Toxicity in Patients Treated with HDR Brachytherapy Boost for Prostate Cancer
38. MOESM2 of A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling
39. A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling
40. Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine
41. 1493: Ultra hypofractionated radiotherapy combined to HDR brachytherapy: optimized prostate cancer therapy.
42. The Dysregulation of the Monocyte/Macrophage Effector Function Induced by Isopropanol Is Mediated by the Defective Activation of Distinct Members of the AP-1 Family of Transcription Factors
43. 81: Effects of Androgen Deprivation Therapy (ADT) Combined with Radiotherapy (EBRT) and HDR-BT Boost on DNA Repair Markers in Prostate Carcinoma.
44. Immunosuppressive Effect of Isopropanol: Down-Regulation of Cytokine Production Results from the Alteration of Discrete Transcriptional Pathways in Activated Lymphocytes
45. MOESM4 of Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine
46. MOESM1 of A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling
47. MOESM1 of Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine
48. MOESM1 of Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine
49. MOESM5 of Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine
50. MOESM4 of Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.